+182.5%
ECHO vs MRNA
+516.4%
-333.9%
-78.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.2% | -3.4% | +1.1% | -2.2% |
| 7D | +5.3% | -10.1% | +15.4% | +5.6% |
| 30D | +2.4% | +126.7% | -124.3% | -1.4% |
| 3M | -21.8% | +184.1% | -205.9% | -25.5% |
| 6M | -16.9% | +143.3% | -160.2% | -20.5% |
| YTD | -16.0% | +359.9% | -375.8% | -21.5% |
| 1Y | +9.3% | +454.2% | -444.9% | +1.4% |
| 3Y | +406.2% | +26.0% | +380.2% | +387.5% |
| 5Y | +251.0% | -70.3% | +321.2% | +236.6% |
| All | +182.5% | +516.4% | -333.9% | +160.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling